1. Scrip
  2. >>Business

Zydus Sees Revlimid Generic Revenues Beyond Q4 As It Waits For Antitrust Suit To Play Out

Acquires Teva Group API Maker Watson

 
• By Vibha Ravi

Zydus, along with Bristol Myers Squibb and generics companies like Mylan, Cipla and Dr. Reddy’s, has been named in an antitrust suit involving BMS’ blockbuster drug Revlimid. For now, it expects revenues from the generic to stretch beyond Q4 FY’23. Meanwhile, a recent acquisition of Watson, which made APIs for the Teva group, should shore up declining API revenues

Growth Story
Zydus Is Planning For Growth, But Will Generic Revlimid Cast A Shadow • Source: Shutterstock

Zydus Lifesciences Limited expects gains from a second quarter launch of a generic to Bristol Myers Squibb Company’s blockbuster oncology drug Revlimid (lenalidomide) to extend beyond the fourth quarter of FY23, which ends 31 March next year.

Multiple Indian companies either have launched or have plans to launch gRevlimid. The first mover Natco Pharma Limited had seen Q1 revenues grow by a whopping 116% year-on-year on the back of gRevlimid, which was launched post a limited volume settlement with the originator

Similarly, Dr. Reddy's Laboratories Ltd.’s which had 180-day exclusivity for lenalidomide capsules in the 2

More from Business

More from Scrip

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.